Blink® Tears Lubricating Eye Drops
Blink® Tears Lubricating Eye Drops
To order this product, please contact your sales rep.
TREAT YOUR PATIENTS' MILD TO MODERATE DRY EYE SYMPTOMS
To give your patients immediate, lasting relief from dry eye symptoms, recommend Blink® Tears Lubricating Eye Drops. With its hypoosmolar, viscoelastic formula, it mimics human tears to restore the tear film and provide exceptional comfort that’s safe.
Blink® Tears Lubricating Eye Drops can help give your patients immediate relief from their dry eye symptoms by reducing hyperosmolarity (high salt levels in tear film).1,2
- Has the lowest osmolarity score when compared to other dry eye drops3
By helping regulate osmolarity levels, Blink® Tears:
- Provides immediate comfort1
- Positively impacts vision quality post surgery4
In a 30-day study comparing Blink® Tears and Systane® Drops, the eyes treated with Blink® Tears exhibited lower osmolarity scores within five minutes of drop instillation on day one. Osmolarity also gradually decreased more over time than in eyes treated with Systane® Drops.1
With its low osmolar formula, Blink® Tears helps all three structures of the tear film: lipid layer, aqueous layer and mucin structure.
UNIQUE VISCOELASTIC FORMULA
With its unique viscoelastic formula, Blink® Tears has properties that make it similar to natural mucin found in human tears.5-7
May deliver better post-operative visual acuity for LASIK patients than Systane® Drops or Optive® Drops.8
- 80 eyes measured for visual quality after LASIK using aberrometry1
- Blink® Tears was shown to positively impact higher-order aberrations, which can affect optical quality and visual outcomes1
Helps stabilize the ocular surface6 by restoring the tear film with every blink.
Thickens and stabilizes the aqueous layer of the tear film by binding a large volume of water (1000x) in a similar way as natural mucin does.9
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR BLINK® TEARS DROPS
Blink® Tears and Blink GelTears® Drops are for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun, and may be used as a protectant against further irritation.
Patients should stop use and contact their eye care practitioner if they experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.
For external use only.
To avoid contamination, do not touch tip of container to any surface. Replace cap after using.
Do not use if solution changes color or becomes cloudy.
Stop use and ask a doctor if:
You experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.
Keep out of the reach of children.
If swallowed, get medical help or contact a Poison Control Center right away.
Instill 1 or 2 drops in the affected eye(s) as needed or as directed by your eye care professional.
Boric Acid; Calcium Chloride; Magnesium Chloride; Potassium Chloride; Purified Water; Sodium Borate; Sodium Chloride; Sodium Chlorite (OcuPure® brand) as a preservative; Sodium Hyaluronate.
Use only if tape seals on top and bottom flaps are intact.
DRUG FACTS FOR BLINK® TEARS DROPS
Active Ingredient Purpose
Polyethylene Glycol 400 0.25% . . . . . . . Eye lubricant
GenTeal®, Systane®, Systane Balance® and Systane Ultra® are trademarks of Alcon Laboratories.
Refresh® and Refresh Optive® are trademarks of Allergan Inc.
- Wasmanski A.D, Kislan, T. Cross-Over Evaluation of Polyethylene Glycol 400 0.4% and 0.25% Artificial Tears in Mild Dry Eye Patients. Poster presented at: The Association for Research and Vision in Ophthalmology Annual Meeting; May 6, 2010, Ft Lauderdale, FL.
- Montani G. Quantitative analysis of corneal staining after a PEG400 eye drop instillation in mild dry eye patients. Poster presented at BCLA, 2010.
- Data on File #135 Blink Formula Grid Comparison (update).
- McDonald MB, Donnenfeld ED, Klyce S. Efficacy of Blink Tears and Systane Artificial Tears on Quality of Vision. Poster presented at: American Academy of Ophthalmology. November 8-11, 2008. Atlanta, GA.
- McMaster TJ, Berry M, Corfield AP, Moles MJ. Atomic Force Microscopy of the Submolecular Architecture of Hydrated Ocular Mucins. Biophys J. 1999;77(1):533-541.
- Huth S, Tran D, Skotnitsky C, Lasswell L, Mahmud P, Kim T. Wavelength-Dependent Optical Interferometry Measurements of Change in Thickness of Apical Corneal Tear Film Following Eye Drop Instillation. Poster presented at ARVO, April 27-May 1, 2008, Fort Lauderdale, Florida.
- Creech JL, Do LT, Fatt I, Radke CJ. In vivo tear-film thickness determination and implications for tear-film stability. Curr Eye Res. 1998;17(11):1058-1066).
- Slade SG. Artificial Tear Preferences in Post-LASIK Patients. Paper, ASCRS. April 3-9, 2009. San Francisco, CA.
- Laurent TC. Structure of hyaluronic acid. In: Balazs EA, editor. Chemistry and molecular biology of the intercellular matrix. London, New York: Academic Press; 1970. p. 703–732.
- Data on File #116 - BEST Data Phase 1 and Phase 2.